Selecta Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company, announced CEO Carsten Brunn's participation in two upcoming virtual investor conferences in November 2020. The conferences include the Jefferies Virtual London Healthcare Conference on November 17, at 9:05 a.m. ET, and the Stifel 2020 Virtual Healthcare Conference on November 18, at 2 p.m. ET. Live webcasts will be accessible via Selecta’s website. The company focuses on developing therapies to manage immune responses using its ImmTOR™ platform, with clinical trials expected to start in early 2021.

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in November:

Jefferies Virtual London Healthcare Conference
Date: Tuesday, November 17, 2020
Presentation time: 9:05 a.m. ET

Stifel 2020 Virtual Healthcare Conference
Date: Wednesday, November 18, 2020
Fireside chat time: 2 p.m. ET

Live webcasts will be available in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With an observed ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in collaboration with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com

For Investors:
Lee M. Stern
Solebury Trout
+1-646-378-2922
lstern@soleburytrout.com

For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com

FAQ

What is the date of the Jefferies Virtual London Healthcare Conference for Selecta Biosciences (SELB)?

The Jefferies Virtual London Healthcare Conference for Selecta Biosciences is on November 17, 2020.

What time will Selecta Biosciences' CEO present at the Jefferies Conference?

Selecta Biosciences' CEO will present at 9:05 a.m. ET.

When is the Stifel 2020 Virtual Healthcare Conference for Selecta Biosciences (SELB)?

The Stifel 2020 Virtual Healthcare Conference is on November 18, 2020.

What time is the fireside chat at the Stifel Conference for Selecta Biosciences (SELB)?

The fireside chat at the Stifel Conference is scheduled for 2 p.m. ET.

Where can I watch the live webcasts for Selecta Biosciences' presentations?

Live webcasts can be watched on Selecta Biosciences' website under the Investors & Media section.

What is SELECTA BIOSCIENCES' focus regarding its ImmTOR™ platform?

Selecta Biosciences focuses on developing tolerogenic therapies to manage unwanted immune responses.